Alembic Pharmaceuticals on Thursday said it has received approval from the US health regulator to market a generic product, used to treat high fluid pressure in the eye, in the US market.
The company has received final approval from the US Food & Drug Administration (USFDA) to market Brimonidine Tartrate Ophthalmic Solution, Alembic Pharmaceuticals said in a statement.
The approved product is therapeutically equivalent to AbbVie Inc's Alphagan P Ophthalmic Solution.
Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
According to IQVIA, Brimonidine Tartrate Ophthalmic Solution has an estimated market size of USD 97 million for twelve months ending December 2022.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
